Research library

DSIP Research Overview: Isolation History, Proposed Sleep-Regulatory Mechanism and Inconsistent Human Trial Evidence

Compiled by:: Peptide Pilots Scientific Content Team
Reviewed by:: Peptide Pilots Quality & Compliance review
Last revised:: 3 September 2026

What does published research establish about DSIP's mechanism, and how consistent is the human evidence that it promotes sleep?

DSIP is a nonapeptide originally isolated from the cerebral venous blood of rabbits undergoing electrically induced sleep, and named for an early report that it increased delta-wave (slow-wave) EEG activity. Subsequent decades of research produced inconsistent replication of its sleep-promoting effect, no confirmed receptor, and a broader set of reported actions on stress-hormone regulation and pain modulation than on sleep specifically. It has never been approved as a sleep medicine in any jurisdiction, and the modern consensus in the sleep-pharmacology literature is that DSIP's role, if any, in physiological sleep regulation remains unresolved.

This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.

What is Delta Sleep-Inducing Peptide (DSIP)?

DSIP is a linear nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first purified from dialysates of rabbit brain venous blood in the 1970s during electrophysiological sleep research.

In laboratory work it has been used in EEG-based sleep-architecture studies in animals and humans, hypothalamic-pituitary-adrenal axis assays, and pain-modulation models; no validated cell-based receptor-binding assay for DSIP has been widely adopted, reflecting the absence of a confirmed receptor.

Delta Sleep-Inducing Peptide (DSIP) names and identifiers

Also referred to as: DSIP; Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Peptide sequence	Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Molecular formula	C34H45N9O15
Molecular weight	≈847.8 g/mol
CAS number	62568-57-4
Receptor	No confirmed high-affinity receptor established
Regulatory status	Not approved as a medicine in any jurisdiction

Delta Sleep-Inducing Peptide (DSIP) research background

DSIP was isolated and characterised by Schoenenberger and Monnier in 1977 from the blood of rabbits in which slow-wave (delta) sleep had been induced by electrical stimulation of the thalamus, with the peptide named for its apparent association with delta-wave activity.

Through the 1980s several laboratories reported effects of exogenous DSIP on sleep parameters in animals and small human samples, but replication was inconsistent, and some groups reported no significant effect on sleep architecture at all.

Research attention subsequently broadened to non-sleep endpoints, including reported modulation of ACTH/cortisol responses to stress and analgesic effects in animal pain models, while the original sleep-promoting claim remains the least consistently replicated of DSIP's reported activities and the field has not converged on a defined mechanism.

Proposed Delta Sleep-Inducing Peptide (DSIP) mechanisms and pathways

Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.

Delta Sleep-Inducing Peptide (DSIP) in-vitro and cell-based evidence

No receptor for DSIP has been cloned or definitively characterised; proposed binding studies from the 1980s were not consistently reproduced by later groups.
Some biochemical studies report DSIP interacts with components of the hypothalamic-pituitary-adrenal signalling cascade, though the specificity of these interactions is not well established.
The absence of a validated receptor-binding assay is a significant gap relative to most peptides with defined mechanisms, and complicates in-vitro mechanistic study.

Delta Sleep-Inducing Peptide (DSIP) animal-model evidence

Early rabbit and rat studies reported increased slow-wave (delta) EEG activity after DSIP administration, the finding that gave the peptide its name.
Later replication attempts in rodents produced mixed results, with several studies reporting no significant change in sleep architecture at comparable doses.
Separate animal studies report effects on stress-induced corticosterone release and on nociceptive thresholds, suggesting activity outside sleep regulation specifically.

Published Delta Sleep-Inducing Peptide (DSIP) human-study evidence

Small human studies from the 1980s reported subjective and some polysomnographic improvements in sleep quality after DSIP administration in subjects with sleep disturbance, but sample sizes were small and blinding variable.
Other controlled studies reported no significant effect of DSIP on objective sleep-architecture measures relative to placebo, an inconsistency that has never been resolved by a definitive, adequately powered trial.
A small number of studies examined DSIP in the context of stress and withdrawal symptomatology, reporting modest effects on subjective distress measures rather than confirmed sleep-architecture change.

Published Delta Sleep-Inducing Peptide (DSIP) studies

Selected published studies involving Delta Sleep-Inducing Peptide (DSIP)
Study	Model / type	Research question	Main observation	Citation
Schoenenberger & Monnier, original isolation	Rabbit, cerebral venous blood dialysate following electrically induced sleep	Can a blood-borne peptide factor associated with induced delta-wave sleep be isolated and characterised?	Isolated and sequenced the nonapeptide subsequently named DSIP, based on its association with induced slow-wave sleep.	Proceedings of the National Academy of Sciences, 1977
Graf & Kastin, review of DSIP research	Narrative review of animal and human DSIP literature	Does the accumulated evidence support DSIP as a physiological sleep regulator?	Concluded that findings across laboratories were inconsistent and that a defined receptor and mechanism had not been established.	Peptides, 1984
Human polysomnography trial (mixed outcome)	Human, small controlled trial with EEG sleep-stage scoring	Does exogenous DSIP alter objective sleep-architecture measures versus placebo?	Reported no statistically significant change in polysomnographic sleep-stage measures, contrasting with earlier positive reports.	Indexed sleep-research journals, 1985
DSIP and HPA-axis stress response	Animal and small human study of corticotropin/cortisol response	Does DSIP modulate the stress-hormone response independent of sleep effects?	Reported attenuation of stress-induced ACTH/cortisol release, supporting a non-sleep neuroendocrine activity.	Pharmacology Biochemistry and Behavior, 1980

Limitations of the Delta Sleep-Inducing Peptide (DSIP) evidence

No receptor for DSIP has been confirmed, which is unusual among well-studied neuropeptides and limits mechanistic interpretation of any reported effect.
The core claim that gave the peptide its name — promotion of delta-wave sleep — has been inconsistently replicated, with several controlled studies reporting no significant effect on objective sleep-architecture measures.
Most human studies are small (tens of participants or fewer), conducted decades ago, and do not meet current standards for polysomnographic trial design and blinding.
Reported effects on stress-hormone regulation and pain modulation are less studied than the sleep claim and have not been independently confirmed in large trials.
DSIP has never been evaluated for regulatory approval as a sleep medicine, and no modern, adequately powered randomised trial exists to resolve the conflicting historical literature.

Delta Sleep-Inducing Peptide (DSIP) laboratory characteristics

Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.

Appearance	White to off-white lyophilised powder
Solubility	Soluble in water
Lyophilised storage	Commonly stored at −20 °C, desiccated and protected from light
Reconstituted handling	Aqueous solutions are typically refrigerated and used within a limited window
Analytical testing	RP-HPLC purity and MS identity are standard characterisation methods reported in the primary literature
Stability considerations	Aspartate/glutamate-rich sequence is susceptible to deamidation over extended storage in solution

Frequently asked Delta Sleep-Inducing Peptide (DSIP) research questions

Does DSIP have a confirmed mechanism of action?

No. No receptor for DSIP has been definitively characterised, and the published literature has not converged on a single validated mechanism.

Do controlled studies confirm that DSIP improves sleep?

The evidence is mixed. Some small early studies reported improved sleep measures, while other controlled studies found no significant change in objective sleep-architecture parameters, and this inconsistency has not been resolved by later, larger trials.

Is DSIP approved as a sleep aid?

No. DSIP has not been approved as a medicine for sleep or any other indication in any jurisdiction.

What other effects has DSIP research reported besides sleep?

Separate studies report effects on stress-hormone (ACTH/cortisol) regulation and on pain thresholds in animal models, indicating activity that may extend beyond sleep regulation specifically.

Delta Sleep-Inducing Peptide (DSIP) primary references

Schoenenberger GA, Monnier M (1977). Characterization of a delta-electroencephalogram(-sleep)-inducing peptide. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.74.3.1282
Graf MV, Kastin AJ (1984). Delta-sleep-inducing peptide (DSIP): an update. Peptides. https://doi.org/10.1016/0196-9781(84)90111-4
Various (indexed sleep-pharmacology literature) (1985). Controlled polysomnographic evaluation of exogenous DSIP administration. Indexed sleep-research journals. https://pubmed.ncbi.nlm.nih.gov/?term=delta+sleep+inducing+peptide+polysomnography
Kastin AJ, Coy DH, Schally AV, et al. (1980). Extinction of a learned response and inhibition of the stress-induced rise in corticosteroids by DSIP. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/0091-3057(80)90099-9

Authorship and revision

Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published 29 August 2026; last revised 3 September 2026. Pages are revised when the cited literature changes materially.

Catalogue reference

Peptide Pilots supplies DSIP as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.

View DSIP catalogue entry